Orchard Therapeutics plc (ORTX): Price and Financial Metrics

Orchard Therapeutics plc (ORTX)

Today's Latest Price: $4.89 USD

0.10 (2.09%)

Updated Nov 27 1:00pm

Add ORTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

See all "A" rated Strong Buy stocks

ORTX Stock Price Chart Interactive Chart >

Price chart for ORTX

ORTX Price/Volume Stats

Current price $4.89 52-week high $15.93
Prev. close $4.79 52-week low $3.76
Day low $4.68 Volume 575,398
Day high $4.95 Avg. volume 588,974
50-day MA $4.45 Dividend yield N/A
200-day MA $6.98 Market Cap 475.62M

Orchard Therapeutics plc (ORTX) Company Bio

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). It operates through the United Kingdom and United States geographical segments. The company was founded in August 2018 and is headquartered in London, the United Kingdom.

ORTX Latest News Stream

Event/Time News Detail
Loading, please wait...

ORTX Latest Social Stream

Loading social stream, please wait...

View Full ORTX Social Stream

Latest ORTX News From Around the Web

Below are the latest news stories about Orchard Therapeutics plc that investors may wish to consider to help them evaluate ORTX as an investment opportunity.

Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript

Orchard Therapeutics plc (ORTX) Q2 2020 Results Conference Call August 06, 2020 08:00 AM ET Company Participants Renee Leck - Investor Relations Bobby Gaspar - Chief Executive Officer Frank Thomas - Chief Operating Officer Conference Call Participants Yaron Werber - Cowen Anupam Rama - JP Morgan Peter Kim - Barclays...

SA Transcripts on Seeking Alpha | August 8, 2020

Orchard Therapeutics: An Undervalued Gene Therapy Company

Orchard Therapeutics (ORTX) was founded in 2015 and has been dedicated to advancing gene therapies for ultra-rare diseases. In 2018, they acquired GSK’s portfolio of gene therapies and became a public company. Orchard now has one of the most extensive and advanced pipelines in the gene therapy space. They have...

Sage Advisors on Seeking Alpha | July 22, 2020

Read More 'ORTX' Stories Here

ORTX Price Returns

1-mo 16.15%
3-mo -24.19%
6-mo -48.53%
1-year -56.34%
3-year N/A
5-year N/A
YTD -64.44%
2019 -12.59%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7117 seconds.